Nasdaq to delist Vincerx Pharma by April 23

SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a market capitalization of just $1.44 million, is set to be delisted from the Nasdaq Stock Market following a notification of non-compliance with the exchange’s listing requirements. The company’s common stock, currently trading at $0.28 and down nearly 95% year-to-date according to InvestingPro data, will be suspended from trading at market open on April 23, 2025, as it did not meet the minimum bid price requirement.

The company received a Delisting Notice from Nasdaq on April 14, 2025, for failing to maintain a closing bid price of at least $1.00 per share over 30 consecutive business days. The stock has fallen dramatically from its 52-week high of $19.88, with InvestingPro analysis showing consistently poor price performance across multiple timeframes. Despite maintaining a current ratio of 1.21 and holding more cash than debt, Vincerx is not entitled to a compliance period and has decided not to appeal the decision. Instead, it plans to file a Form 25 with the Securities and Exchange Commission (SEC) around April 28, 2025, to voluntarily delist and deregister its common stock, followed by a Form 15 filing.

Earlier, Nasdaq had inadvertently suspended trading of Vincerx’s stock on April 16, 2025, instead of the scheduled April 23. The company worked with Nasdaq to resume trading on Monday, April 21, 2025, which will continue until April 22, 2025.

Vincerx’s board of directors concluded that dissolving, liquidating, and winding up the company’s business and affairs was in the best interest of its shareholders. Consequently, the company will not seek to list its common stock on another national securities exchange or market. Following the completion of its liquidation process, Vincerx will distribute any remaining assets to its stockholders after settling its debts.

This press release contains forward-looking statements regarding Vincerx’s intentions and the expected timing of filings and trading suspensions. These statements are subject to risks and uncertainties that could cause actual events to differ materially. Vincerx has stated that it may also engage in the out-licensing or monetization of its assets and intellectual property if possible.

The information presented is based on a press release statement from Vincerx Pharma, Inc. and does not include any speculative content. The company, headquartered in San Mateo, California, with a research facility in Monheim, Germany, is undergoing an orderly dissolution process as it prepares to exit the Nasdaq Stock Market. InvestingPro subscribers have access to 10 additional key insights about VINC, including detailed financial health scores and comprehensive analysis of the company’s current situation.

In other recent news, Vincerx Pharma has announced the termination of its proposed merger with QumulusAI, a decision that coincides with the initiation of wind-down activities. The company has cited adverse market dynamics as a factor in this strategic shift, and plans to monetize its assets and explore out-licensing opportunities. Vincerx Pharma’s board has authorized these actions following an annual report that may have highlighted the challenges the company faces. Additionally, Vincerx has entered into an agreement with H.C. Wainwright & Co. to sell up to $30 million of its common stock in an at-the-market equity offering, providing the company with the flexibility to raise capital as needed. The company’s acting CEO, Raquel Izumi, expressed gratitude for the contributions of those involved in Vincerx’s journey and acknowledged the benefits their therapies have provided to cancer patients. Meanwhile, Vincerx had previously revealed plans for a reverse triangular merger with QumulusAI, which would have made QumulusAI a publicly traded entity, but this plan has now been canceled. The company has not disclosed specific details on the timeline for its wind-down or the expected financial outcomes from asset monetization efforts. Investors are advised to consider these developments when evaluating Vincerx Pharma’s current position and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.